C
CardioMEMS
Biotech & Life Sciences · Atlanta, United States · Founded 2001
Wireless sensing and communication technology solutions for severe chronic cardiovascular diseases in the human body MoreLess
Abbott's cardiovascular division specializes in developing advanced medical devices and technologies aimed at improving patient care in the cardiovascular field. The company serves healthcare professionals and institutions by providing a wide range of products, including stents, heart valves, and remote monitoring systems for chronic heart failure patients. Operating in the global healthcare market, Abbott leverages its extensive research and development capabilities to innovate and bring effective solutions to market. The business model revolves around the sale of these medical devices and associated services, generating revenue through direct sales to hospitals and healthcare providers, as well as through ongoing support and maintenance contracts. Abbott's cardiovascular products are designed to meet the needs of physicians and patients, ensuring better health outcomes and streamlined medical procedures. Keywords: cardiovascular devices, patient care, medical technology, stents, heart valves, remote monitoring, chronic heart failure, healthcare professionals, global market, innovation.
Company overview
CardioMEMS company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2001
- Headquarters
- Atlanta, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 76.5
- Investment activity
- 2 companies · latest Jun 2013
- Capital deployed
- $60M
- Preferred round
- SERIES E
Valuation & funding
CardioMEMS funding history
Company financing events and reported valuations.
Growth signals
CardioMEMS website traffic
Latest recorded traffic for CardioMEMS is 180K monthly website visits, up 0% over the last three months. CardioMEMS's team declined 15.2% over the past year.
Comparisons
CardioMEMS compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
CardioMEMS investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Spinal ModulationMenlo Park, United StatesMedical device company developing spinal cord neurostimulator systems for the treatment of chronic intractable pain
$180Mvaluation
Micell TechnologiesDurham, United StatesBiomedical device company developing interventional cardiology systems for vascular drug delivery
$247Mvaluation
Talent graph
CardioMEMS's talent
Source: Dealroom Talent Intelligence.
Investors
14 investors on CardioMEMS's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where CardioMEMS has talent and traffic
team presence
In the news
Latest news about CardioMEMS
Recent press, funding announcements, and product moves mentioning CardioMEMS — open to read from the original sources.
Market sentiment
What the market is saying about CardioMEMS
An AI-synthesized read of the highest-engagement posts about CardioMEMS on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CardioMEMS’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.